{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:14:13Z","timestamp":1791249253160,"version":"4.1.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Background: The recent development of nonradioactive automated assays for serum parathyroid hormone (PTH) and 25-hydroxyvitamin D (25OHD) has made measurement of these two hormones possible in many laboratories. In this study, we compared two new assays for PTH and 25OHD adapted on an automated analyzer, the LIAISON\u00ae, with two manual immunoassays used worldwide.<\/jats:p>\n               <jats:p>Methods: We studied 228 osteoporotic patients, 927 healthy individuals, 38 patients with primary hyperparathyroidism, and 167 hemodialyzed patients. Serum PTH was measured with the Allegro\u00ae and the LIAISON assays, and 25OHD was measured with DiaSorin RIA and the LIAISON assay. Regression analysis was used to calculate decision thresholds for the LIAISON assays that were equivalent to those of the Allegro PTH and DiaSorin 25OHD assays.<\/jats:p>\n               <jats:p>Results: The 25OHD concentrations obtained with the LIAISON assay and the RIA in osteoporotic patients were well correlated (r = 0.83; P &amp;lt;0.001). Regression and Bland\u2013Altman analyses suggested that the LIAISON 25OHD assay reads lower than the DiaSorin RIA at low concentrations but higher at high concentrations. However, the cutoff (50 nmol\/L) used in our laboratories to define vitamin D insufficiency with the DiaSorin RIA is applicable to the LIAISON 25OHD assay. In 927 healthy individuals, the 3rd\u201397th percentile intervals were 3\u201380 ng\/L and 13\u2013151 nmol\/L for the LIAISON PTH and 25OHD concentrations, respectively. However, 506 individuals (54.6%) were vitamin D-insufficient; we therefore considered only the 421 individuals with a LIAISON 25OHD &amp;gt;50 nmol\/L as eligible for the reference population for the LIAISON PTH assay. In this group, the 3rd\u201397th percentile interval for LIAISON PTH was 3\u201351 ng\/L. Considering upper reference limits of 46 and 51 ng\/L for the Allegro and LIAISON assays, respectively, the frequency of above-normal PTH concentrations in patients with primary hyperparathyroidism was similar in both assays. Regression analysis between serum PTH measured by the Allegro and LIAISON assays in 167 hemodialyzed patients and the corresponding Bland\u2013Altman analysis of these data suggest that the LIAISON PTH assay tends to read higher than the Allegro assay at low concentrations but lower at high concentrations (&amp;gt;300 ng\/L).<\/jats:p>\n               <jats:p>Conclusions: Because clinical decision limits for both PTH and 25OHD should be assay specific, we propose equivalences between these assays and two manual assays used worldwide. These assay-specific decision limits should help potential users of the LIAISON PTH and 25OHD assays.<\/jats:p>","DOI":"10.1373\/clinchem.2004.037606","type":"journal-article","created":{"date-parts":[[2004,11,25]],"date-time":"2004-11-25T01:13:58Z","timestamp":1101345238000},"page":"395-400","source":"Crossref","is-referenced-by-count":40,"title":["Assay-Specific Decision Limits for Two New Automated Parathyroid Hormone and 25-Hydroxyvitamin D Assays"],"prefix":"10.1093","volume":"51","author":[{"given":"Jean-Claude","family":"Souberbielle","sequence":"first","affiliation":[{"name":"Laboratoire d\u2019Explorations Fonctionnelles, Ho\u0302pital Necker-Enfants Malades, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ve\u0301ronique","family":"Fayol","sequence":"first","affiliation":[{"name":"Laboratoire Marcel Me\u0301rieux, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Sault","sequence":"first","affiliation":[{"name":"Laboratoire Marcel Me\u0301rieux, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethel","family":"Lawson-Body","sequence":"first","affiliation":[{"name":"Laboratoire d\u2019Explorations Fonctionnelles, Ho\u0302pital Necker-Enfants Malades, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre\u0301","family":"Kahan","sequence":"first","affiliation":[{"name":"Service de Rhumatologie, Ho\u0302pital Cochin, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Cormier","sequence":"first","affiliation":[{"name":"Service de Rhumatologie, Ho\u0302pital Cochin, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,2,1]]},"reference":[{"key":"2020022800535319400_R1","doi-asserted-by":"crossref","unstructured":"Webb A, Kline L, Holick M. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D synthesis in human skin. J Clin Endocrinol Metab1988;67:373-378.","DOI":"10.1210\/jcem-67-2-373"},{"key":"2020022800535319400_R2","doi-asserted-by":"crossref","unstructured":"Quesada JM, Coopmans W, Ruiz B, Aljam P, Jans I, Bouillon R. Influence of vitamin D on parathyroid function in the elderly. J Clin Endocrinol Metab1992;75:494-501.","DOI":"10.1210\/jcem.75.2.1639950"},{"key":"2020022800535319400_R3","doi-asserted-by":"crossref","unstructured":"M\u2019Buyamba-Kabangu JR, Fagard R, Lijnen P, Bouillon R, Lissens W, Amery A. Calcium, vitamin D-endocrine system, and parathyroid hormone in black and white males. Calcif Tissue Int1987;41:70-74.","DOI":"10.1007\/BF02555247"},{"key":"2020022800535319400_R4","doi-asserted-by":"crossref","unstructured":"Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev2001;22:477-501.","DOI":"10.1210\/edrv.22.4.0437"},{"key":"2020022800535319400_R5","doi-asserted-by":"crossref","unstructured":"Malabanan A, Veronikis I, Holick M. Redefining vitamin D insufficiency. Lancet1998;351:805-806.","DOI":"10.1016\/S0140-6736(05)78933-9"},{"key":"2020022800535319400_R6","doi-asserted-by":"crossref","unstructured":"Chapuy MC, Preziosi P, Maamer M, Arnaud S, Galan P, Hercberg S, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int1997;7:439-443.","DOI":"10.1007\/s001980050030"},{"key":"2020022800535319400_R7","doi-asserted-by":"crossref","unstructured":"Holick M. Vitamin D: the underappreciated D-lightful hormone that is important for skeletal and cellular health. Curr Opin Endocrinol Diabetes2002;9:87-98.","DOI":"10.1097\/00060793-200202000-00011"},{"key":"2020022800535319400_R8","doi-asserted-by":"crossref","unstructured":"Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence?. Br J Nutr2003;89:552-572.","DOI":"10.1079\/BJN2003837"},{"key":"2020022800535319400_R9","doi-asserted-by":"crossref","unstructured":"Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr1999;69:842-856.","DOI":"10.1093\/ajcn\/69.5.842"},{"key":"2020022800535319400_R10","doi-asserted-by":"crossref","unstructured":"Souberbielle JC, Cormier C, Kindermans C, Gao P, Cantor T, Forette F, et al. Vitamin D status and redefining serum parathyroid hormone reference range in the elderly. J Clin Endocrinol Metab2001;86:3086-3090.","DOI":"10.1210\/jc.86.7.3086"},{"key":"2020022800535319400_R11","doi-asserted-by":"crossref","unstructured":"Lips P, Chapuy MC, Dawson-Hughes B, Pols H, Holick M. An international comparison of serum 25-hydroxy vitamin D measurements. Osteoporos Int1999;9:394-397.","DOI":"10.1007\/s001980050162"},{"key":"2020022800535319400_R12","doi-asserted-by":"crossref","unstructured":"Hollis BW. Comparison of commercially available (125)I-based RIA methods for the determination of circulating 25-hydroxyvitamin D. Clin Chem2000;46:1657-1661.","DOI":"10.1093\/clinchem\/46.10.1657"},{"key":"2020022800535319400_R13","doi-asserted-by":"crossref","unstructured":"Bilezikian J, Potts , El-Hadj Fuleihan G, Kleerekoper M, Neer R, Peacock M, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab2002;87:5353-5361.","DOI":"10.1210\/jc.2002-021370"},{"key":"2020022800535319400_R14","doi-asserted-by":"crossref","unstructured":"Nussbaum S, Zahradnik R, Lavigne J, Brennan G, Nozawa-Ung K, Kim L, et al. Highly sensitive two-site immunoradiometric assay for parathyrin and its clinical utility in evaluating patients with hypercalcemia. Clin Chem1987;33:1364-1367.","DOI":"10.1093\/clinchem\/33.8.1364"},{"key":"2020022800535319400_R15","doi-asserted-by":"crossref","unstructured":"Hollis BW, Karnerud J, Selvaag S, Lorenz J, Napoli JL. Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer. Clin Chem1993;39:529-533.","DOI":"10.1093\/clinchem\/39.3.529"},{"key":"2020022800535319400_R16","unstructured":"John E, Schwartz G, Dreon D, Koo J. Vitamin D and breast cancer risk: the NHANES I epidemiologic follow-up study, 1971\u20131975 to 1992. Cancer Epidemiol Biomarkers Prev1999;8:399-406."},{"key":"2020022800535319400_R17","doi-asserted-by":"crossref","unstructured":"Bostick R, Potter J, Sellers T, McKenzie D, Kushi L, Folsom A. Relation of calcium, vitamin D, and dairy food intake to incidence of colon cancer among older women. Am J Epidemiol1993;137:1302-1317.","DOI":"10.1093\/oxfordjournals.aje.a116640"},{"key":"2020022800535319400_R18","doi-asserted-by":"crossref","unstructured":"Ahonen M, Tenkanen L, Teppo L, Hakama M, Tuohlmaa P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels. Cancer Causes Control2000;11:847-852.","DOI":"10.1023\/A:1008923802001"},{"key":"2020022800535319400_R19","doi-asserted-by":"crossref","unstructured":"Hyppo\u0308nen E, La\u0308a\u0308ra E, Reunanen A, Ja\u0308rvelin MR, Virtanen S. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet2001;358:1501-1503.","DOI":"10.1016\/S0140-6736(01)06580-1"},{"key":"2020022800535319400_R20","doi-asserted-by":"crossref","unstructured":"Cantorna M, Hayes C, Deluca H. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A1996;93:7861-7864.","DOI":"10.1073\/pnas.93.15.7861"},{"key":"2020022800535319400_R21","doi-asserted-by":"crossref","unstructured":"Cantorna M, Hayes C, DeLuca H. 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr1998;128:68-72.","DOI":"10.1093\/jn\/128.1.68"},{"key":"2020022800535319400_R22","doi-asserted-by":"crossref","unstructured":"Visser M, Deeg D, Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab2003;88:5766-5772.","DOI":"10.1210\/jc.2003-030604"},{"key":"2020022800535319400_R23","doi-asserted-by":"crossref","unstructured":"Guillemant J, Taupin P, Le HT, Taright N, Allemandou A, Pe\u0301re\u0300s G, et al. Vitamin D status during puberty in French healthy male adolescents. Osteoporos Int1999;10:222-225.","DOI":"10.1007\/s001980050219"},{"key":"2020022800535319400_R24","doi-asserted-by":"crossref","unstructured":"Newman DJ, Ashby JP. Clinical and laboratory evaluation of a two-site immunoradiometric assay for intact parathyroid hormone. Ann Clin Biochem1988;25:654-660.","DOI":"10.1177\/000456328802500610"},{"key":"2020022800535319400_R25","doi-asserted-by":"crossref","unstructured":"Ratcliffe WA, Heath DA, Ryan S, Jones SR. Performance and diagnostic application of a two-site immunoradiometric assay for parathyrin in serum. Clin Chem1989;35:1957-1961.","DOI":"10.1093\/clinchem\/35.9.1957"},{"key":"2020022800535319400_R26","doi-asserted-by":"crossref","unstructured":"Endres D, Villanueva R, Sharp C, Jr, Singer F. Immunochemiluminometric and immunoradiometric determinations of intact and total immunoreactive parathyrin: performance in the differential diagnosis of hypercalcemia and hypoparathyroidism. Clin Chem1991;37:162-168.","DOI":"10.1093\/clinchem\/37.2.162"},{"key":"2020022800535319400_R27","doi-asserted-by":"crossref","unstructured":"Blind E, Schmidt-Gayk H, Scharla S, Flentje D, Fischer S, Go\u0308hring U, et al. Two-site assay of intact parathyroid hormone in the investigation of primary hyperparathyroidism and other disorders of calcium metabolism compared with a mid-region assay. J Clin Endocrinol Metab1988;67:353-360.","DOI":"10.1210\/jcem-67-2-353"},{"key":"2020022800535319400_R28","doi-asserted-by":"crossref","unstructured":"Carnevale V, Dionisi S, Nofroni I, Romagnoli E, Paglia F, De Geronimo S, et al. Potential utility of a new IRMA for parathyroid hormone in postmenopausal patients with primary hyperparathyroidism. Clin Chem2004;50:626-631.","DOI":"10.1373\/clinchem.2003.026328"},{"key":"2020022800535319400_R29","unstructured":"Glendenning P, Gutteridge DH, Retallack RW, Stuckey BG, Kermode DG, Kent GN. High prevalence of normal total calcium and intact PTH in 60 patients with proven primary hyperparathyroidism: a challenge to current diagnostic criteria. Aust NZ J Med1998;28:173-178."},{"key":"2020022800535319400_R30","doi-asserted-by":"crossref","unstructured":"Silverberg S, Gao P, Brown I, LoGerfo P, Cantor T, Bilezikian J. Clinical utility of an immunoradiometric assay for parathyroid hormone (1\u201384) in primary hyperparathyroidism. J Clin Endocrinol Metab2003;88:4725-4730.","DOI":"10.1210\/jc.2002-021266"},{"key":"2020022800535319400_R31","doi-asserted-by":"crossref","unstructured":"Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, et al. The spectrum of bone disease in end-stage renal failure\u2014an evolving disorder. Kidney Int1993;43:436-442.","DOI":"10.1038\/ki.1993.64"},{"key":"2020022800535319400_R32","unstructured":"K\/DOKI guidelines for the management of renal osteodystrophy. Am J Kidney Dis2003;42(Suppl 3):S1-S201."},{"key":"2020022800535319400_R33","doi-asserted-by":"crossref","unstructured":"Lepage R, Roy L, Brossard JH, Rousseau L, Dorais C, Lazure C, et al. A non (1\u201384) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem1998;44:805-809.","DOI":"10.1093\/clinchem\/44.4.805"},{"key":"2020022800535319400_R34","doi-asserted-by":"crossref","unstructured":"Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, et al. A novel mechanism for skeletal resistance in uremia. Kidney Int2000;58:753-761.","DOI":"10.1016\/S0085-2538(15)47156-X"},{"key":"2020022800535319400_R35","doi-asserted-by":"crossref","unstructured":"John M, Goodman W, Gao P, Cantor T, Salusky I, Ju\u0308ppner H. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implication for PTH measurements in renal failure. J Clin Endocrinol Metab1999;84:4287-4290.","DOI":"10.1210\/jcem.84.11.6236"},{"key":"2020022800535319400_R36","doi-asserted-by":"crossref","unstructured":"Monier-Fauge\u0300re MC, Geng Z, Mawad H, Friedler RM, Gao P, Cantor T, et al. Improved assessment of bone turnover by the PTH (1\u201384)\/C-PTH fragments ratio in ESRD patients. Kidney Int2001;60:460-468.","DOI":"10.1046\/j.1523-1755.2001.00949.x"},{"key":"2020022800535319400_R37","doi-asserted-by":"crossref","unstructured":"Coen G, Bonucci E, Ballanti P, Balducci A, Calabria S, Nicolai G, et al. PTH 1\u201384 and PTH \u201c7\u201384\u201d in the noninvasive diagnosis of bone disease. Am J Kidney Dis2002;40:348-354.","DOI":"10.1053\/ajkd.2002.34519"},{"key":"2020022800535319400_R38","doi-asserted-by":"crossref","unstructured":"Salusky I, Goodman W, Kuizon B, Lavigne J, Zahranik R, Gales B, et al. Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int2003;63:1801-1808.","DOI":"10.1046\/j.1523-1755.2003.00915.x"},{"key":"2020022800535319400_R39","doi-asserted-by":"crossref","unstructured":"Martin K, Olgaard K, . on behalf of the Bone Turnover Work Group. Diagnosis, assessment and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis2004;43:558-565.","DOI":"10.1053\/j.ajkd.2003.12.003"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/51\/2\/395\/32681959\/clinchem0395.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/51\/2\/395\/32681959\/clinchem0395.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T05:55:08Z","timestamp":1582869308000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/51\/2\/395\/5629723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,1]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2005,2,1]]},"published-print":{"date-parts":[[2005,2,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2004.037606","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2005,2,1]]},"published":{"date-parts":[[2005,2,1]]}}}